Co-amorphous solid dispersion systems of Lacidipine (cas 103890-78-4)-spironolactone with improved dissolution rate and enhanced physical stability

Add time:07/23/2019    Source:sciencedirect.com

Co-amorphous solid dispersion (C-ASD) systems have attracted great attention to improve the solubility of poorly soluble drugs, but the selection of an appropriate stabilizer to stabilize amorphous forms is still a huge challenge. Herein, C-ASD system of two clinical combined used drugs (lacidipine (LCDP) and spironolactone (SPL)) as stabilizers to each other, was prepared by solvent evaporation method. The effects of variation in molar ratio of LCDP and SPL (3:1, 1:1, 1:3, 1:6, and 1:9) on the drug release characteristics were explored. Polarized light microscopy (PLM), powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) were employed to evaluate the solid states. Prepared C-ASDs were further studied for their stability under the high humidity (RH 92.5%). Further analysis of C-ASDs via Fourier-transform infrared spectroscopy (FTIR) and Raman spectroscopy confirmed that hydrogen bond interactions between the two drugs played a significant role in maintaining the stability of the C-ASDs systems. Moreover, molecular dynamic (MD) simulations provided a clear insight into the stability mechanism at the molecular level. This study demonstrated the novel drug-drug C-ASDs systems is a promising formulation strategy for improved dissolution rate and enhanced physical stability of poorly soluble drugs.

We also recommend Trading Suppliers and Manufacturers of Lacidipine (cas 103890-78-4). Pls Click Website Link as below: cas 103890-78-4 suppliers

Prev:Rapidly dissolving Lacidipine (cas 103890-78-4) nanoparticle strips for transbuccal administration
Next:Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral Lacidipine (cas 103890-78-4) formulations in dogs)